PetVivo Holdings, Inc. Set to Unveil Q2 Financial Results and Conduct a Conference Call

MINNEAPOLIS, MN — On November 9th, 2023, PetVivo Holdings, Inc. PETV, an emerging leader in the biomedical device industry specializing in solutions for animal health, officially announced the date it will release its second quarter financial results for the period ending September 30th, 2023. The announcement is scheduled for after the market closes on Tuesday, November 14, 2023. Following the release of the financial report, PETV will hold a conference call at 4:00 p.m. CT (5:00 p.m. ET) to discuss the findings.

Shareholders and interested parties can attend the live webcast by registering through the link provided on PetVivo’s Investor Relations site. A replay of the call will be made available at the same web address after the event. For additional accessibility, participants can dial in using the provided telephone numbers and conference ID.

Conference Call Details

Date: Tuesday, November 14, 2023
Time: 4:00 p.m CT (5:00 pm ET)
Dial-in number: +1 669 444 9171
Conference ID: 88693059825
Passcode: 802278

Investor Relations and Disclosure Information

PetVivo has embraced the use of its Investor Relations website as a primary channel for significant nonpublic company information. In line with Regulation FD, the company consistently informs investors through this platform, in addition to traditional outlets such as press releases, SEC filings, and public conference calls.

About PetVivo Holdings, Inc.

Based in Minneapolis, Minnesota, PETV operates in the veterinary biotechnology sphere, focusing on the manufacturing and licensing of medical devices and therapeutics for companion animals. The company's go-to-market approach capitalizes on translating modality from human therapies to animal treatments in a time and capital-efficient manner. This strategy benefits from the typically shorter regulatory pathways for veterinary devices compared to pharmaceuticals.

PETV boasts a promising pipeline of products and holds a portfolio of twenty patents that cover its proprietary biomaterials, devices, production processes, and usage methods. Among its product lineup, SPRYNG^™ with OsteoCushion^™ Technology stands out, currently offered on the market. This veterinary-administered injectable aims to alleviate conditions like lameness and osteoarthritis in dogs and horses.

Forward-Looking Statements

This announcement includes 'forward-looking statements' within the legal framework set by the Securities Act of 1933 and the Securities Exchange Act of 1934, reflecting the company's expectations for future performance and market opportunities. Such statements are subject to multiple uncertainties and risks, and investors are cautioned that actual results may differ from the projected performance.

The company reaffirms its commitment to maintaining open communication with its investors, consistently disclosing essential operational information, and adhering to best practices in corporate governance.

PetVivo, financial, results, biomedical, conference, call, investment, veterinary, biotechnology, NASDAQ, PETV